2015 Cutting Edge of Transplantation - Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
Looking back at the promise of gene therapy and regulatory cells, what have we learned from our past experiences and how does this inform us of where future development in transplantation will take us?
• Have the studies in gene therapy and regulatory cells delivered on their promise to transform transplantation?
• Are we on the threshold of a new era of development in cellular/tissue augmentation and organogenesis?
• How successful will transplant research be in repurposing drugs for other indications?
The AST’s CEOT 2015 meeting brought together leading clinicians and scientists from academia and industry, from within and outside the field of transplantation, to discuss the current and future challenges in transplantation with a focus on cell engineering, gene and drug therapies.
Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.